Trial Profile
The comparison of the efficacy and safety of pirfenidone and nintedanib in patients with idiopathic pulmonary fibrosis
Status:
Not yet recruiting
Phase of Trial:
Phase II
Latest Information Update: 28 Jul 2021
Price :
$35
*
At a glance
- Drugs Nintedanib (Primary) ; Pirfenidone (Primary)
- Indications Idiopathic pulmonary fibrosis
- Focus Therapeutic Use
- 17 May 2016 New trial record